123 related articles for article (PubMed ID: 12563530)
1. Distribution of liposome-encapsulated antimony in dogs.
Schettini DA; Costa Val AP; Souza LF; Demicheli C; Rocha OG; Melo MN; Michalick MS; Frézard F
Braz J Med Biol Res; 2003 Feb; 36(2):269-72. PubMed ID: 12563530
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic and parasitological evaluation of the bone marrow of dogs with visceral leishmaniasis submitted to multiple dose treatment with liposome-encapsulated meglumine antimoniate.
Schettini DA; Costa Val AP; Souza LF; Demicheli C; Rocha OG; Melo MN; Michalick MS; Frézard F
Braz J Med Biol Res; 2005 Dec; 38(12):1879-83. PubMed ID: 16302103
[TBL] [Abstract][Full Text] [Related]
3. Mixed formulation of conventional and pegylated liposomes as a novel drug delivery strategy for improved treatment of visceral leishmaniasis.
Azevedo EG; Ribeiro RR; da Silva SM; Ferreira CS; de Souza LE; Ferreira AA; de Oliveira E Castro RA; Demicheli C; Rezende SA; Frézard F
Expert Opin Drug Deliv; 2014 Oct; 11(10):1551-60. PubMed ID: 24962630
[TBL] [Abstract][Full Text] [Related]
4. Disposition of antimony after the administration of N-methylglucamine antimoniate to dogs.
Valladares JE; Alberola J; Esteban M; Arboix M
Vet Rec; 1996 Feb; 138(8):181-3. PubMed ID: 8677619
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of meglumine antimoniate after administration of a multiple dose in dogs experimentally infected with Leishmania infantum.
Valladares JE; Riera C; Alberola J; Gállego M; Portús M; Cristòfol C; Franquelo C; Arboix M
Vet Parasitol; 1998 Feb; 75(1):33-40. PubMed ID: 9566092
[TBL] [Abstract][Full Text] [Related]
6. Reduced tissue parasitic load and infectivity to sand flies in dogs naturally infected by Leishmania (Leishmania) chagasi following treatment with a liposome formulation of meglumine antimoniate.
Ribeiro RR; Moura EP; Pimentel VM; Sampaio WM; Silva SM; Schettini DA; Alves CF; Melo FA; Tafuri WL; Demicheli C; Melo MN; Frézard F; Michalick MS
Antimicrob Agents Chemother; 2008 Jul; 52(7):2564-72. PubMed ID: 18458133
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of liposome-encapsulated meglumine antimonate after intramuscular and subcutaneous administration in dogs.
Valladares JE; Freixas J; Alberola J; Franquelo C; Cristofol C; Arboix M
Am J Trop Med Hyg; 1997 Oct; 57(4):403-6. PubMed ID: 9347953
[TBL] [Abstract][Full Text] [Related]
8. Antileishmanial activity of liposome-encapsulated meglumine antimonate in the dog.
Chapman WL; Hanson WL; Alving CR; Hendricks LD
Am J Vet Res; 1984 May; 45(5):1028-30. PubMed ID: 6732008
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic Efficacy of a Mixed Formulation of Conventional and PEGylated Liposomes Containing Meglumine Antimoniate, Combined with Allopurinol, in Dogs Naturally Infected with Leishmania infantum.
Dos Santos CCP; Ramos GS; De Paula RC; Faria KF; Moreira POL; Pereira RA; Melo MN; Tafuri WL; Demicheli C; Ribeiro RR; Azevedo EG; Do Monte-Neto R; Da Silva SM; Frézard F
Antimicrob Agents Chemother; 2020 Jun; 64(7):. PubMed ID: 32284386
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of combined therapy with liposome-encapsulated meglumine antimoniate and allopurinol in treatment of canine visceral leishmaniasis.
da Silva SM; Amorim IF; Ribeiro RR; Azevedo EG; Demicheli C; Melo MN; Tafuri WL; Gontijo NF; Michalick MS; Frézard F
Antimicrob Agents Chemother; 2012 Jun; 56(6):2858-67. PubMed ID: 22411610
[TBL] [Abstract][Full Text] [Related]
11. Hepatic fibropoiesis in dogs naturally infected with Leishmania (Leishmania) infantum treated with liposome-encapsulated meglumine antimoniate and allopurinol.
Castro RS; de Amorim IFG; Pereira RA; Silva SM; Pinheiro LJ; Pinto AJW; Azevedo EG; Demicheli C; Caliari MMV; Mosser DM; Michalick MSM; Frezard FJG; Tafuri WL
Vet Parasitol; 2018 Jan; 250():22-29. PubMed ID: 29329619
[TBL] [Abstract][Full Text] [Related]
12. Use of topical liposomes containing meglumine antimoniate (Glucantime) for the treatment of L. major lesion in BALB/c mice.
Kalat SA; Khamesipour A; Bavarsad N; Fallah M; Khashayarmanesh Z; Feizi E; Neghabi K; Abbasi A; Jaafari MR
Exp Parasitol; 2014 Aug; 143():5-10. PubMed ID: 24780938
[TBL] [Abstract][Full Text] [Related]
13. Disposition of antimony in rhesus monkeys infected with Leishmania braziliensis and treated with meglumine antimoniate.
Friedrich K; Vieira FA; Porrozzi R; Marchevsky RS; Miekeley N; Grimaldi G; Paumgartten FJ
J Toxicol Environ Health A; 2012; 75(2):63-75. PubMed ID: 22129235
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of antimony during treatment of visceral leishmaniasis with sodium stibogluconate or meglumine antimoniate.
Chulay JD; Fleckenstein L; Smith DH
Trans R Soc Trop Med Hyg; 1988; 82(1):69-72. PubMed ID: 2845611
[TBL] [Abstract][Full Text] [Related]
15. Tissue distribution of residual antimony in rats treated with multiple doses of meglumine antimoniate.
Coelho DR; Miranda ES; Saint'Pierre TD; Paumgartten FJ
Mem Inst Oswaldo Cruz; 2014 Jul; 109(4):420-7. PubMed ID: 25075781
[TBL] [Abstract][Full Text] [Related]
16. Novel methods for the encapsulation of meglumine antimoniate into liposomes.
Frézard F; Michalick MS; Soares CF; Demicheli C
Braz J Med Biol Res; 2000 Jul; 33(7):841-6. PubMed ID: 10881061
[TBL] [Abstract][Full Text] [Related]
17. Disposition of antimony and aminosidine in dogs after administration separately and together: implications for therapy of leishmaniasis.
Belloli C; Ceci L; Carli S; Tassi P; Montesissa C; De Natale G; Marcotrigiano G; Ormas P
Res Vet Sci; 1995 Mar; 58(2):123-7. PubMed ID: 7761689
[TBL] [Abstract][Full Text] [Related]
18. Comparative evaluation of meglumine antimoniate encapsulated in a mixture of conventional and PEGylated liposomes and immunotherapy using an anti-canine IL-10 receptor-blocking monoclonal antibody on canine visceral leishmaniasis.
Cardoso JMO; Brito RCF; Mathias FAS; Reis LES; Vieira JFP; Ostolin TLVDP; Andrade HM; Ramos GS; Frézard F; Aguiar-Soares RDO; Roatt BM; Reis AB
Mol Immunol; 2022 Jan; 141():70-78. PubMed ID: 34814056
[TBL] [Abstract][Full Text] [Related]
19. Improved targeting of antimony to the bone marrow of dogs using liposomes of reduced size.
Schettini DA; Ribeiro RR; Demicheli C; Rocha OG; Melo MN; Michalick MS; Frézard F
Int J Pharm; 2006 Jun; 315(1-2):140-7. PubMed ID: 16549281
[TBL] [Abstract][Full Text] [Related]
20. Disposition of antimony and aminosidine combination after multiple subcutaneous injections in dogs.
Belloli C; Crescenzo G; Carli S; Zaghini A; Mengozzi G; Bertini S; Ormas P
Vet J; 1999 May; 157(3):315-21. PubMed ID: 10328843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
